Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC
Accepted 2022-06-02 00:00:00 ET · period of report 2022-05-31 · accession 0001127602-22-016409 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-06-02 | 2022-05-31 | BCRX | ASELAGE STEVE | Dir | A - Grant | $9.31 | +569 | 33.7K | +2% | +$5,297 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-31 | A | A | 569 | $9.31 | 33,728 | D | — | — | (F1) Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250, prorated to $10,597.83 based on the increase in the annual retainer fee effective April 18, 2022. |